No OS Difference Between Tivozanib and Sorafenib for Advanced Renal Cell Carcinoma

Share this content:

(ChemotherapyAdvisor) – No significant difference in overall survival (OS) was found between tivozanib and sorafenib in patients with advanced renal cell carcinoma (RCC), according to final data from the phase 3 TIVO-1 trial and its open-label, multicenter extension study, reported during the 2013 Genitourinary Cancers Symposium in Orlando, FL.

“The high rate of utilization of second-line tivozanib in patients following disease progression on sorafenib may have affected the OS outcome,” noted Robert John Motzer MD, of the Genitourinary Service, Memorial Sloan-Kettering Cancer Center, New York, NY, and colleagues. Previously, the TIVO-1 results had shown “superior progression-free survival and overall response rate” for tivozanib compared with sorafenib.

The study randomly assigned 517 patients to tivozanib 1.5 mg/day (3 weeks on; 1 week off) or sorafenib 400 mg/day (twice daily, continuously). In the extension study, patients who experienced disease progression on sorafenib were eligible to receive tivozanib, and those who progressed on tivozanib received regional standard-of-care treatment.

“Final OS analysis was planned to be conducted after all patients had died or were lost to follow-up, or when all patients in follow-up had been on study for at least 2 years, whichever occurred first,” Dr. Motzer explained.

In this case, final OS analysis occurred 2 years after the last patient was enrolled. Of the 219 deaths, 118 patients (45.4%) were enrolled in the tivozanib arm and 101 (39.3%) in the sorafenib arm (stratified hazard ratio, 1.245; 95% CI: 0.954–1.624; P=0.105). The trend favored the sorafenib arm, he noted.

Median OS was 28.8 months (95% CI: 22.5–NA) for tivozanib and 29.3 months (95% CI: 29.3–NA) for sorafenib. Of 257 patients on sorafenib, 155 (60.3%) had started next-line tivozanib at the time of the analysis.

The 2013 Genitourinary Cancers Symposium is co-sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO).

Abstract ID: NCT01030783

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs